Apellis Pharma

Apellis Pharmaceuticals is a global biopharmaceutical company dedicated to developing life-changing therapies by pioneering targeted C3 therapies. Focused on diseases propelled by excessive activation of the complement cascade, Apellis operates in hematology, ophthalmology, and nephrology. With a vision to revolutionize treatment for debilitating diseases, Apellis has introduced two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide.

Committed to advancing courageous science and driven by compassion, Apellis boasts a pipeline of nearly a dozen clinical and pre-clinical programs aimed at unlocking the potential of targeting C3 across a myriad of serious diseases. The company's culture is centered on caring for the greater good of society, with a firm belief in corporate responsibility as foundational to its vision. Apellis Pharmaceuticals is led by a team of experts dedicated to developing transformative medicines and is committed to becoming a sustainable company that delivers on its vision